全文获取类型
收费全文 | 582篇 |
免费 | 49篇 |
国内免费 | 10篇 |
专业分类
儿科学 | 30篇 |
妇产科学 | 1篇 |
基础医学 | 8篇 |
口腔科学 | 2篇 |
临床医学 | 18篇 |
内科学 | 29篇 |
特种医学 | 11篇 |
外国民族医学 | 1篇 |
外科学 | 12篇 |
综合类 | 45篇 |
现状与发展 | 1篇 |
预防医学 | 1篇 |
药学 | 112篇 |
中国医学 | 16篇 |
肿瘤学 | 354篇 |
出版年
2023年 | 8篇 |
2022年 | 6篇 |
2021年 | 16篇 |
2020年 | 12篇 |
2019年 | 14篇 |
2018年 | 15篇 |
2017年 | 24篇 |
2016年 | 25篇 |
2015年 | 25篇 |
2014年 | 26篇 |
2013年 | 79篇 |
2012年 | 29篇 |
2011年 | 36篇 |
2010年 | 32篇 |
2009年 | 33篇 |
2008年 | 33篇 |
2007年 | 46篇 |
2006年 | 41篇 |
2005年 | 35篇 |
2004年 | 26篇 |
2003年 | 29篇 |
2002年 | 18篇 |
2001年 | 12篇 |
2000年 | 7篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 2篇 |
排序方式: 共有641条查询结果,搜索用时 31 毫秒
1.
目的研究西妥昔单抗联合伊利替康治疗晚期胃癌对患者核因子κB(NF-κB)、正常上皮细胞特异性1(NES1)蛋白表达及生存期的影响。方法将80例晚期胃癌患者根据治疗方法不同分为研究组和对照组各40例,研究组利用西妥昔单抗联合伊立替康治疗,对照组单独利用西妥昔单抗治疗,比较两组患者癌胚抗原(CEA)NF-κB、NES1表达情况、治疗效果、不良反应发生情况和生存情况。结果研究组治疗后有效率为85.00%(34/40),与对照组的70.00%(28/40)比较,差异无统计学意义(P﹥0.05)。治疗前,两组患者CEA、NES1、NF-κB水平比较,差异均无统计学意义(P﹥0.05)。治疗后,研究组患者CEA水平明显低于对照组,NES1、NF-κB水平明显高于对照组,差异均有统计学意义(P﹤0.01)。研究组患者不良反应总发生率为20.00%(8/40),低于对照组的42.50%(17/40),差异有统计学意义(P﹤0.05)。研究组治疗后1年中位生存期为8.26个月(95%CI:6.154~9.985),长于对照组的6.54个月(95%CI:5.112~8.013),差异有统计学意义(P﹤0.05);研究组治疗后复发4例,少于对照组的10例,差异有统计学意义(P﹤0.05)。结论西妥昔单抗联合伊立替康治疗晚期胃癌具有良好的疗效,提高了NF-κB、NES1表达水平,降低了不良反应发生率并延长患者的生存期,对晚期胃癌患者的诊疗有指导意义。 相似文献
2.
3.
Side‐Effects of Irinotecan (CPT‐11), the Clinically Used Drug for Colon Cancer Therapy,Are Eliminated in Experimental Animals Treated with Latex Proteins from Calotropis procera (Apocynaceae) 下载免费PDF全文
Nylane Maria Nunes de Alencar Flávio da Silveira Bitencourt Ingrid Samantha Tavares de Figueiredo Patrícia Bastos Luz Roberto César P. Lima‐Júnior Karoline Sabóia Aragão Pedro Jorge Caldas Magalhães Gerly Anne de Castro Brito Ana Paula Fragoso de Freitas Marcio Viana Ramos 《Phytotherapy research : PTR》2017,31(2):312-320
Intestinal mucositis (IM) is the critical side effect of irinotecan (CPT‐11), which is the front‐line drug used for the treatment of colorectal cancer. This study aimed to evaluate the effectiveness of latex proteins (LP) from Calotropis procera to prevent IM and diarrhea in animals. Swiss mice were treated daily with saline or LP (1, 5, or 50 mg/kg, i.v.) 24 h prior to CTP‐11 (75 mg/kg/4 days, i.p) and for additional 6 days. Animal survival, body weight variation, and diarrhea were registered. After animal sacrifice (day 7 post first injection of CPT‐11), intestinal samples were collected to study morphology and inflammatory parameters. Animals given LP exhibited improved parameters (survival, body weight, and absence of diarrhea) as compared with the CPT‐11 control. The severity of IM observed in animals given CPT‐11 was reduced in animals treated with LP. Treatment with LP also prevented the reduction in the villus/crypt ratio promoted by CPT‐11. The rise in MPO activity and pro‐inflammatory cytokines, over‐contractility of the smooth muscle, and diarrhea were all abrogated in LP‐treated mice. Markedly reduced immunostaining intensity for COX‐2, TNF‐α, IL‐1β, iNOS, and NF‐κB was observed in the intestinal tissue of animals treated with LP. The side‐effects of CPT‐11 were eliminated by LP treatment in experimental animals and improved clinical parameters characteristic of IM All known biochemical pathogenesis. Copyright © 2016 John Wiley & Sons, Ltd. 相似文献
4.
目的 研究甘草泻心汤对化疗相关腹泻小鼠肠道菌群的影响。方法 将小鼠随机分为对照组、模型组、洛哌丁胺(阳性药,0.4 mg·kg-1)组和甘草泻心汤高、低剂量(16.4、4.1 g·kg-1)组;采用连续4 d ip 55 mg·kg-1伊立替康诱导小鼠化疗相关腹泻模型;记录小鼠首次排便时间、稀便级、稀便率和腹泻指数;采用试剂盒测定小鼠肠道消化酶活力及炎症因子水平;采用高通量测序技术分析结肠内容物肠道菌群变化。结果 与对照组比较,模型组小鼠首次排便时间显著缩短(P<0.01),稀便级、稀便率和腹泻指数显著升高(P<0.01);消化酶乳酸脱氢酶(LDH)、淀粉酶(AMS)和脂肪酶(LPS)活力显著降低(P<0.01);炎症因子白细胞介素1β (IL-1β)、环氧化酶2 (COX-2)、细胞间黏附分子1 (ICAM-1)和肿瘤坏死因子α (TNF-α)水平显著升高(P<0.01);肠道菌群α多样性Simpson指数显著升高(P<0.05);肠道菌群β多样性差异较大;变形菌门、梭杆菌门、变形菌纲、梭杆菌纲、肠杆菌目、梭杆菌目、拟杆菌科、丹毒丝菌科、埃格特菌科和拟杆菌属丰度显著升高(P<0.01),Muribaculaceae和norank_f__Muribaculaceae丰度显著降低(P<0.01)。与模型组比较,甘草泻心汤高、低剂量组小鼠首次排便时间显著延长(P<0.05、0.01)、稀便率和腹泻指数显著降低(P<0.05、0.01),高剂量组稀便级显著降低(P<0.01);高、低剂量组各消化酶活力显著回升(P<0.05、0.01);高、低剂量组各炎症因子水平显著降低(P<0.05、0.01);高剂量组Simpson指数显著降低(P<0.05),β多样性更趋近对照组,显著回调各优势物种丰度的显著性变化(P<0.05、0.01)。结论 甘草泻心汤对于伊立替康诱导的腹泻小鼠具有明显的治疗作用,可能是其通过调整腹泻小鼠肠道菌群实现。 相似文献
5.
6.
Daniel H Berrocal Germán E González Celina Morales Ricardo J Gelpi Liliana R Grinfeld 《Catheterization and cardiovascular interventions》2006,68(1):89-96
OBJECTIVE: To assess the effect of irinotecan-eluting stents (IS) on neointimal growth in the aortas of hypercholesterolemic rabbits and to determine other local histopathological effects such as necrosis, fibrin, and inflammatory reaction. METHODS: Phosphorylcholine-coated stents were deployed in the aortas of hypercholesterolemic rabbits. Group 1 (control; n = 8) received unloaded stents, group 2 (n = 7) and group 3 (n = 9) received IS with 0.046 mg and 1.29 mg of irinotecan, respectively. Eight weeks after implantation the rabbits were killed. Neointimal thickness (NT) was assessed by morphometry. Semiquantitative injury score (from 0 to 3+) was used to analyze inflammatory infiltrate, fibrin deposits, and necrosis in the stented segments. RESULTS: NT was reduced only in high-doses IS (G1, 167.4 +/- 20.8 mu; G2, 170.24 +/- 21.2 mu; G3, 111.56 +/- 12.7 mu; P < 0.05, G3 vs G1 and G2). Necrosis decreased significantly with IS [1.00 +/- 0.10 in G1 to 0.33 +/- 0.07 and 0.02 +/- 0.01 in G2 and G3, respectively] only in the media layer. The inflammatory infiltrate was present in the three layers of aortas from G1, but only decreased significantly in the intimae layer of the high-dose group [1.50 +/- 0.15 in G1 vs 1.00 +/- 0.18 in G3, P < 0.05]. CONCLUSION: Stents loaded with high-dose irinotecan inhibit NT in the aortas of hypercholesterolemic rabbits. This effect was accompanied by decreased inflammatory infiltrate and media necrosis. 相似文献
7.
BackgroundMetastatic colorectal cancer (mcrc) commonly affects elderly people, an understudied subset of patients. We analyzed the survival impact of the first and subsequent lines of chemotherapy in eligible non-trial patients 70 years of age and older with mcrc treated between 2004 and 2012.MethodsThis single-centre retrospective analysis estimated overall survival (os) and progression-free survival (pfs) using the Kaplan–Meier method. Multivariate analysis was used to adjust for age, sex, Eastern Cooperative Oncology Group performance status, score on the Charlson comorbidity index, dependency in activities of daily living, and exposure to 1 or more chemotherapy doublets, capecitabine alone, or best supportive care (bsc).ResultsOf 109 patients identified, 29 elected bsc, and 80 received chemotherapy. In multivariate analysis, age was not associated with os [hazard ratio (hr): 0.99; 95% confidence interval (ci): 0.92 to 1.05], but a performance status of 2 or higher was associated with a decreased likelihood of survival (hr: 3.12; 95% ci: 1.87 to 5.76), and exposure to 1 or more doublets was associated with improved survival (hr: 0.33; 95% ci: 0.17 to 0.66). In univariate analysis, a trend toward improved os was observed for first-line doublet chemotherapy compared with capecitabine (hr: 0.66; 95% ci: 0.41 to 1.07), and pfs was superior (hr: 0.46; 95% ci: 0.26 to 0.84). Compared with exposure to 1 doublet, exposure to the 3 potential cytotoxic chemotherapies was not associated with improved os (hr: 0.77; 95% ci: 0.41 to 1.43). The incidence of neutropenia with first-line folfiri was 40%; the incidences of bevacizumab-related arterial and venous thrombosis were both 8%.ConclusionsExposure to 1 or more doublet chemotherapies for mcrc was associated with better outcomes in non-trial patients 70 years of age and older. Elderly patients treated with palliative chemotherapy and bevacizumab should be monitored carefully for arterial and venous thrombotic events. 相似文献
8.
Barbara Jonchère Alexandra Vétillard Bertrand Toutain David Lam Anne Charlotte Bernard Cécile Henry Sophie De Carné Trécesson Erick Gamelin Philippe Juin Catherine Guette Olivier Coqueret 《Oncotarget》2015,6(1):409-426
Induction of senescence by chemotherapy was initially characterized as a suppressive response that prevents tumor cell proliferation. However, in response to treatment, it is not really known how cells can survive senescence and how irreversible this pathway is. In this study, we analyzed cell escape in response to irinotecan, a first line treatment used in colorectal cancer that induced senescence. We detected subpopulations of cells that adapted to chemotherapy and resumed proliferation. Survival led to the emergence of more transformed cells that induced tumor formation in mice and grew in low adhesion conditions. A significant amount of viable polyploid cells was also generated following irinotecan failure. Markers such as lgr5, CD44, CD133 and ALDH were downregulated in persistent clones, indicating that survival was not associated with an increase in cancer initiating cells. Importantly, malignant cells which resisted senescence relied on survival pathways induced by Mcl-1 signaling and to a lesser extent by Bcl-xL. Depletion of Mcl-1 increased irinotecan efficiency, induced the death of polyploid cells, prevented cell emergence and inhibited growth in low-adhesion conditions. We therefore propose that Mcl-1 targeting should be considered in the future to reduce senescence escape and to improve the treatment of irinotecan-refractory colorectal cancers. 相似文献
9.
W Ichikawa K Uehara K Minamimura C Tanaka Y Takii H Miyauchi S Sadahiro K Fujita T Moriwaki M Nakamura T Takahashi A Tsuji K Shinozaki S Morita Y Ando Y Okutani M Sugihara T Sugiyama Y Ohashi Y Sakata 《British journal of cancer》2015,112(10):1709-1716
Background:
In Asians, the risk of irinotecan-induced severe toxicities is related in part to UGT1A1*6 (UGT, UDP glucuronosyltransferase) and UGT1A1*28, variant alleles that reduce the elimination of SN-38, the active metabolite of irinotecan. We prospectively studied the relation between the UGT1A1 genotype and the safety of irinotecan-based regimens in Japanese patients with advanced colorectal cancer, and then constructed a nomogram for predicting the risk of severe neutropenia in the first treatment cycle.Methods:
Safety data were obtained from 1312 patients monitored during the first 3 cycles of irinotecan-based regimen in a prospective observational study. In development of the nomogram, multivariable logistic regression analysis was used to test the associations of candidate factors to severe neutropenia in the first cycle. The final nomogram based on the results of multivariable analysis was constructed and validated internally using a bootstrapping technique and externally in an independent data set (n=350).Results:
The UGT1A1 genotype was confirmed to be associated with increased risks of irinotecan-induced grade 3 or 4 neutropenia and diarrhoea. The final nomogram included type of regimen, administered dose of irinotecan, gender, age, UGT1A1 genotype, Eastern Cooperative Oncology Group performance status, pre-treatment absolute neutrophil count, and total bilirubin level. The model was validated both internally (bootstrap-adjusted concordance index, 0.69) and externally (concordance index, 0.70).Conclusions:
Our nomogram can be used before treatment to accurately predict the probability of irinotecan-induced severe neutropenia in the first cycle of therapy. Additional studies should evaluate the effect of nomogram-guided dosing on efficacy in patients receiving irinotecan. 相似文献10.